LOGIN  |  REGISTER
Viking Therapeutics

Nemaura Medical (NASDAQ: NMRD) Stock Quote

Last Trade: US$0.0002
Volume: 0
5-Day Change: -99.90%
YTD Change: -99.91%
Market Cap: US$8K

Latest News From Nemaura Medical

Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background After thorough analysis, Nemaura Medical’s... Read More
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1 st , 2024,... Read More
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans. Recognizing the challenges associated with equity... Read More
Company CEO to discuss development at 1pm EST on 15 th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical , developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with... Read More
Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update. Corporate Highlights:... Read More
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc . (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Mr Rozanov is a specialist in the field of... Read More
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference. The... Read More
LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc . (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provided an update regarding the status of its compliance with Nasdaq continued listed standards and anticipated next steps to maintain... Read More
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc . (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced interim results from its metabolic health program. The primary objective of the study was to establish whether a metabolic... Read More
LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc . (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting diabetes management and personalized lifestyle coaching programs, today announced it will be participating at the HLTH 2023 conference, in Las Vegas, in October. The Company’s... Read More
LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized diabetes management and metabolic health programs, today announced it has recently completed a 100-patient study across 4 cohorts of 25 diabetic patients for sugarBEAT ® and provided... Read More
Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announced SFDA (Saudi Food and Drug Authority) approval of sugarBEAT ® , its non-invasive wearable glucose sensor. The news... Read More
Loughborough, England, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended June 30, 2023 and provided a business update. Corporate Highlights:... Read More
Loughborough, England, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces today that it has secured a further $6.5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements, from its existing lender.... Read More
Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and financial results for the fiscal year ended March 31, 2023. Corporate Highlights: Entered into... Read More
LOUGHBOROUGH, June 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces the next commercialization stage of its proBEAT ™ sensor and AI-based feedback platform, augmenting the BEAT ™ diabetes program. The pilots are intended as a precursor to revenue generating... Read More
LOUGHBOROUGH, June 22, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces that it will be participating at the upcoming Collision Conference being held at the Enercare Centre in Toronto, Canada on June 26-29, 2023. The Collision Conference brings together leading technology... Read More
LOUGHBOROUGH, June 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized diabetes management and metabolic health programs, today announces it will exhibit and provide product demonstrations of its non-invasive daily-wear glucose sensor platform at the 83... Read More
LOUGHBOROUGH, March 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today announces that CEO Dr. Faz Chowdhury will participate in a fireside chat on March 29, 2023 at 10am ET and being hosted by EF Hutton... Read More
LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today announced that it now includes insulin on the list of drugs under the DuoPack Commercial License Agreement with its licensee,... Read More
LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today announced that on February 23, 2023, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC... Read More
Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today releases its financial results for the quarter ending December 31, 2022 and provides a business update. Recent Corporate... Read More
Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, announces that CEO Dr. Faz Chowdhury will participate in a fireside chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Conference that is being held... Read More
LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today announced the close of its previously announced registered direct offering (the “Registered Direct Offering”) with two healthcare-focused... Read More
LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today announced it has entered into a definitive agreement with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of... Read More
Nemaura to integrate its proBEAT TM glucose sensors with HealthFleet’s proven RestoreHealth wellness program targeted at U.S. market LOUGHBOROUGH, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today... Read More
Average weight loss of 3.7 pounds and an average BMI reduction of 0.6 after 10 weeks in initial patients LOUGHBOROUGH, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc . (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, announces initial results from patient... Read More
Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announces that CEO Dr. Faz Chowdhury will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference being held on January 18 -19,... Read More
C4 Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB